| Pharmaceutical Information |
| Drug Name |
Teduglutide |
| Drug ID |
BADD_D02137 |
| Description |
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012. |
| Indications and Usage |
Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. |
| Marketing Status |
Not Available |
| ATC Code |
A16AX08 |
| DrugBank ID |
DB08900
|
| KEGG ID |
D06053
|
| MeSH ID |
C494910
|
| PubChem ID |
16139605
|
| TTD Drug ID |
D00RCI
|
| NDC Product Code |
17337-0264; 68875-0102; 41524-0009; 63557-1031; 68875-0101; 68875-0103; 68225-087; 68594-001 |
| Synonyms |
teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2 |
|
| Chemical Information |
| Molecular Formula |
C164H252N44O55S |
| CAS Registry Number |
197922-42-2 |
| SMILES |
CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C
(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O
)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)
C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=
O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(C
C(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C
NC(=O)C(CC5=CN=CN5)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
|
|
| ADRs Induced by Drug |
|
|
